NYSE:ZYME

Zymeworks Stock Insider Trading

Healthcare > Biotechnology

Buy ZYME

*Your capital is at risk

$24.35

+0.240 (+1.00%)

At Close: Jun 03, 2026

Zymeworks Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 51.85. In total, the insiders bought 4.91M and sold 187.93K ZYME shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	51.85
● Buy	4.91M shares
● Sell	187.93K shares
90% Buy Activity Strong Negative Correlation
Sell Signal Low Confidence Jan 12, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 51.85. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Cherry Brian N Director	Director	23 000 Value: $532.7K
Jan 12, 2026 Buy	Performance Stock Unit A-Award	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	66 000 Value: $1.53M
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	70 000 Value: $1.62M
Jan 12, 2026 Sell	Common Stock S-Sale	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	6 120 Value: $138.8K
Jan 12, 2026 Buy	Common Stock M-Exempt	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	17 666 Value: $409.1K
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	47 000 Value: $1.09M
Jan 12, 2026 Buy	Restricted Stock Unit M-Exempt	Hollywood Mark EVP & Chief Operating Officer	C-Suite Officer	17 666 Value: $409.1K
Jan 12, 2026 Buy	No securities are beneficially owned	Cherry Brian N Director	Director	0 Value: $0
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Galbraith Kenneth Chair & CEO	CEO / President	216 000 Value: $5.00M
Jan 12, 2026 Buy	Performance Stock Unit A-Award	Galbraith Kenneth Chair & CEO	CEO / President	222 000 Value: $5.14M
Jan 12, 2026 Sell	Common Stock S-Sale	Galbraith Kenneth Chair & CEO	CEO / President	30 424 Value: $689.8K
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Moore Paul Andrew Chief Scientific Officer	Officer	47 000 Value: $1.09M
Jan 12, 2026 Sell	Common Stock S-Sale	Moore Paul Andrew Chief Scientific Officer	Officer	9 560 Value: $216.8K
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Moore Paul Andrew Chief Scientific Officer	Officer	70 000 Value: $1.62M
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Mahony Susan Director	Director	7 700 Value: $178.3K
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Cesano Alessandra Director	Director	7 700 Value: $178.3K
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Cesano Alessandra Director	Director	11 500 Value: $266.3K
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Landry Robert E Director	Director	7 700 Value: $178.3K
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Landry Robert E Director	Director	11 500 Value: $266.3K
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Neu Kelvin Director	Director	7 700 Value: $178.3K
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Neu Kelvin Director	Director	11 500 Value: $266.3K
Jan 12, 2026 Buy	Restricted Stock Unit A-Award	Ciongoli Gregory Austin Director	Director	7 700 Value: $178.3K
Jan 12, 2026 Buy	Stock Option (Right to Buy) A-Award	Ciongoli Gregory Austin Director	Director	11 500 Value: $266.3K
Jan 12, 2026 Sell	Common Stock S-Sale	Smith Jeffrey T L EVP & Chief Medical Officer	Officer	9 310 Value: $211.1K
Jan 12, 2026 Buy	Restricted Stock Unit M-Exempt	Smith Jeffrey T L EVP & Chief Medical Officer	Officer	17 666 Value: $409.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ZYMEWORKS INC

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 ...

Read Full Profile Here